Juan Antonio Barcia

Juan Antonio Barcia

Auto-generated profile, based on publicly available information

Juan Antonio Barcia

Department of Neurosurgery, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Universidad Complutense de Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
STSofía Torres
Sofía Torres
MLMar Lorente
Mar Lorente
FRFátima Rodríguez-Fornés
Fátima Rodríguez-Fornés
SHSonia Hernández-Tiedra
Sonia Hernández-Tiedra
MSMaría Salazar
María Salazar
GDGuillermo Velasco Díez
Guillermo Velasco Díez
Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ9-Tetrahydrocannabinol (THC), the major active ingredient of marijuana, and other cannabinoid receptor agonists inhibit tumor growth in animal models of cancer, including glioma, an effect that relies, at least in part, on the stimulation of autophagy-mediated apoptosis in tumor cells. Here, we show that the combined administration of THC and temozolomide (TMZ; the benchmark agent for the management of GBM) exerts a strong antitumoral action in glioma xenografts, an effect that is also observed in tumors that are resistant to TMZ treatment. Combined administration of THC and TMZ enhanced autophagy, whereas pharmacologic or genetic inhibition of this process prevented TMZ + THC-induced cell death, supporting that activation of autophagy plays a crucial role on the mechanism of action of this drug combination. Administration of submaximal doses of THC and cannabidiol (CBD; another plant-derived cannabinoid that also induces glioma cell death through a mechanism of action different from that of THC) remarkably reduces the growth of glioma xenografts. Moreover, treatment with TMZ and submaximal doses of THC and CBD produced a strong antitumoral action in both TMZ-sensitive and TMZ-resistant tumors. Altogether, our findings support that the combined administration of TMZ and cannabinoids could be therapeutically exploited for the management of GBM. Mol Cancer Ther; 10(1); 90–103. ©2011 AACR.

1 March 2009 in Neuroscience
Verified
Journal Article
Closed access
VHV. Hernández-Rabaza
V. Hernández-Rabaza
MLMaria Llorens-Martín
Maria Llorens-Martín
CVC. Velázquez-Sánchez
C. Velázquez-Sánchez
AFAntonio Ferragud
Antonio Ferragud
AAA. Arcusa
A. Arcusa
JCJuan J. Canales
Juan J. Canales

1 October 2008 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
VHV. Hernández-Rabaza
V. Hernández-Rabaza
LHL. Hontecillas-Prieto
L. Hontecillas-Prieto
CVC. Velázquez-Sánchez
C. Velázquez-Sánchez
AFAntonio Ferragud
Antonio Ferragud
APA. Pérez-Villaba
A. Pérez-Villaba
JCJuan J. Canales
Juan J. Canales

1 May 2019 in Brain Stimulation
Verified
Journal Article
Closed access
JBJuan A. Barcia
Juan A. Barcia
JAJosué M. Avecillas-Chasín
Josué M. Avecillas-Chasín
CNCristina Nombela
Cristina Nombela
RARocío Arza
Rocío Arza
JGJulia García-Albea
Julia García-Albea
BSBryan A. Strange
Bryan A. Strange

18 July 2006 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
LDL. Domínguez‐Escribà
L. Domínguez‐Escribà
VHV. Hernández‐Rabaza
V. Hernández‐Rabaza
MSM. Soriano‐Navarro
M. Soriano‐Navarro
JBJ. A. Barcia
J. A. Barcia
FRFrancisco J. Romero
Francisco J. Romero
JCJuan J. Canales
Juan J. Canales

1 April 2017 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PRPaola A. Rivera-Rivera
Paola A. Rivera-Rivera
MRMarcos Rios-Lago
Marcos Rios-Lago
SSSandra Sanchez-Casarrubios
Sandra Sanchez-Casarrubios
OSOsman Salazar
Osman Salazar
MYMiguel Yus
Miguel Yus
JBJuan A. Barcia
Juan A. Barcia
OBJECTIVE: The extent of resection is the most important prognostic factor following brain glioma surgery. However, eloquent areas within tumors limit the extent of resection and, thus, critically affect outcomes. The authors hypothesized that presurgical suppression of the eloquent areas within a tumor by continuous cortical electrical stimulation, coupled with appropriate behavioral training (“prehabilitation”), would induce plastic reorganization and enable a more extensive resection. METHODS: The authors report on 5 patients harboring gliomas involving eloquent brain areas within tumors as identified on intraoperative stimulation mapping. A grid of electrodes was placed over the residual tumor, and continuous cortical electrical stimulation was targeted to the functional areas. The stimulation intensity was adjusted daily to provoke a mild functional impairment while the function was intensively trained. RESULTS: The stimulation intensity required to impair function increased progressively in all patients, and all underwent another operation a mean of 33.6 days later (range 27–37 days), when the maximal stimulation voltage in all active contacts induced no functional deficit. In all cases, a substantially more extensive resection of the tumor was possible. Intraoperative mapping and functional MRI demonstrated a plastic reorganization, and most previously demonstrated eloquent areas within the tumor were silent, while there was new functional activation of brain areas in the same region or toward the contralateral hemisphere. CONCLUSIONS: Prehabilitation with continuous cortical electrical stimulation and appropriate behavioral training prior to surgery in patients with WHO Grade II and III gliomas affecting eloquent areas accelerate plastic changes. This can help maximize tumor resection and, thus, improve survival while maintaining function.